ical entity diagnosed in adulthood. We present our experience on biofeedback in 3 dysfunctional voiding cases diagnosed in adulthood. Material and Methods: Three male pa- tients that were 20, 23 and 26 years old presented with LUTS for 5-8 years. Neur- ourologic assessment, cystoscopy, imaging of the urinary tract, MRI of spinal tract and urodynamics (free uroflowmetry + PVR, uroflowmetry combined with exter- nal sphincter EMG and videourodynamics) and revealed abnormal activity in external urethral striated sphincter during voiding in the absence of any neurological or ana- tomic abnormality and was considered as dysfunctional voiding. Only one patient had positive family history. Biofeedback treatment was performed one session per week for 36, 10, and 13 weeks, respec- tively, after the diagnosis. Treatment out- comes were assesses by subjective re- sponse, bladder diary and urodynamics. Results: No patient demonstrated subjec- tive improvement during/ after biofeed- back therapy. No significant difference was found between pre- and post bladder diaries or urodynamic parameters. Conclusions: Our series including 3 pa- tients assessed the outcomes of biofeed- back treatment for dysfunctional voiding diagnosed rarely in adulthood, revealed no improvement in the clinical table. UP-02.012 The Advantages of Bipolar Vaporization in the Therapy of Benign Prostatic Hyperplasia Bucuras V, Bardan R, Cumpanas A, Secasan C, Balarie C, Georgiadis M Dept. of Urology, Clinical Emergency Hospital, Timisoara, Romania Introduction and Objective: Bipolar vaporization of the prostate is a new mini- mally invasive technique, with potentially significant advantages, compared with mo- nopolar transurethral resection of the prostate. The objective of our study was to evaluate the efficacy and safety of bipo- lar vaporization as a therapy for benign prostatic hyperplasia. Materials and Methods: Between 15 March and 15 December 2010 we have performed 68 transurethral resections of the prostate, using the bipolar vaporiza- tion electrode and the high-frequency gen- erator produced by Karl Storz Endoskope, Germany. We have performed the follow- ing preoperative evaluations: transrectal ultrasonographic measurement of the prostate volume, International Prostate Symptom Score (IPSS), post-void residual volume (PVRV), maximum flow rate (Qmax), hemoglobin and serum sodium levels. The evaluations were repeated at one month after the intervention. Results: The average preoperative vol- ume was 54.7 ml and the average re- sected volume was 36.3 ml. Mean postop- erative catheterization time was 42.6 hours, while the mean decrease of hemo- globin was 1.1 g/dL, and the sodium level decreased with only 1.8mmol/L. A per- centage of 86.8% of patients resumed mic- turition after catheter removal. Significant hematuria was observed in 11 patients, but no patient needed re-intervention or blood transfusions. No TUR syndrome was observed after bipolar vaporization. The IPSS score has decreased after one month from 21.5 to 6.2 (p0.01), the PVRV from 121.3 ml to 26.7 ml (p0.01), while Qmax increased from 6.5 ml/s to 21.6 ml/s (p0.01). Conclusion: Bipolar vaporization of the prostate is an effective method, providing higher safety, smooth and efficient coagu- lation and less bleeding than the monopo- lar standard resection technique. UP-02.013 Bipolar RF Thermotherapy for Chronic Prostatitis: 2 Years’ Follow-Up Beck C Dortmund, Germany Introduction and Objectives: Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) is a major health care burden which causes significant suffering to the patients and constitutes a sizeable work- load for the urologists. Several conserva- tive types of treatments are available but many patients are not relieved of their painful symptoms for long periods of time. For the last 2 years, we started to use a minimal invasive treatment based on thermotherapy with the Tempro system (Direx-Initia). We are here reporting our follow up results after 12 and 24 months follow-up. Material and Methods: We used Bipolar Radiofrequency Thermal Treatment with a protocol of 53.5 degrees Celsius for 60 minutes. All patients had symptoms at least 3 to 6 months, and have tried differ- ent drugs, such as Ciprofloxacin, Tamsu- losine and NSAID, without success. The way to analyze quantitatively the potential improvement was using the NIH Symp- toms Score. We have treated 60 relatively young patients, aged between 28 to 57 years (average 42 years). The mean pros- tate size was 40 cc, out of which 33% were NIH Category II and 67% were Cate- gory IIIA. In fact we have also treated sev- eral patients Category IIIB, but since 90% of them failed, we stopped treating these type of patients. Results: The results after 12 months are as follows: Patients whose score de- creased 50% or more were 26 (43%) and the ones that did not decreased 50% or more were 34 (57%). The mean Total CPSI Score improved from 23.1 to 16.3 (30%). Mean pain domain score improved from 11.7 to 6.9 (41%) and Quality of Life domain score from 6.7 to 4.7 (30%) Acute complications were: 4 UTI treated with Antibiotics, 2 “de novo” voiding symp- toms with conservative management and 3 urinary retentions, treated with indwell- ing catheter for 3-5 days. Thirty-seven pa- tients were available for follow at 24 months. Patients whose score decreased 50% or more were 18 (49%) and the ones that did not decrease 50% or more were 19 (51%). The mean Total CPSI Score im- proved from 23.4 to 14.0 (40%). Mean pain domain score improved from 12.1 to 5.7 (53%) and Quality of Life domain score from 6.9 to 4.4 (37%). Conclusions: Considering that chronic prostatitis is a challenging illness, these results, with an overall success rate of 43% at 12 months and 49% at 24 months are very encouraging and show that re- sults are maintained over this period of time. Perineal and/or perianal pain, as well as orchalgia, are substantially im- proved in the majority of the patients. The Tempro treatments it is a simple, safe and effective procedure with minimal side effects. Longer follow-up and a larger trial is required to explore in depth the poten- tial of this treatment. UP-02.014 Safety of Tamsulosin OCAS™ plus Solifenacin in Men with LUTS Associated with BPH in the SATURN Trial Haab F 1 , van Kerrebroeck P 2; Klecka J 3; Vik V 4; Angulo J 5; Garcia-Hernandez A 6; Klaver M 6 1 Hôpital Tenon, Paris, France; 2 Maastricht University Medical Center, Maastricht, The Netherlands; 3 University Teaching Hospital, Plzen, Czech Republic; 4 Thomayer University Hospital, Prague, Czech Republic; 5 Hospital Universitario de Getafe, Getafe, Spain; 6 Astellas Pharma Global Development Europe, Leiderdorp, The Netherlands Introduction and Objective: The safety of the oral controlled absorption system UNMODERATED POSTER SESSIONS S264 UROLOGY 78 (Supplement 3A), September 2011